SwePub
Sök i LIBRIS databas

  Utökad sökning

id:"swepub:oai:DiVA.org:oru-93857"
 

Sökning: id:"swepub:oai:DiVA.org:oru-93857" > Effects of Peroral ...

  • Tofiq, avin,1996-School of Medicine, Örebro University, Örebro, Sweden,Örebro Univ, Sch Med, Örebro, Sweden. (författare)

Effects of Peroral Omega-3 Fatty Acid Supplementation on Cerebrospinal Fluid Biomarkers in Patients with Alzheimer's Disease : A Randomized Controlled Trial-The OmegAD Study

  • Artikel/kapitelEngelska2021

Förlag, utgivningsår, omfång ...

  • IOS Press,2021
  • printrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:DiVA.org:oru-93857
  • https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-93857URI
  • https://doi.org/10.3233/JAD-210007DOI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:147806770URI
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-457931URI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • Funding agencies:Pronova Biocare A/SFunds of CapioOdd FellowSwedish Society of PhysiciansLion's SwedenStohne's FoundationAlzheimer Drug Discovery Foundation (ADDF), USA RDAPB-201 809-2016615 2018092016862ALF ALFGBG-715986European Union Joint Program for Neurodegenerative Disorders JPND2019466-236European Research Council (ERC) 681712  Swedish State Support for Clinical Research ALFGBG-720931UK Dementia Research Institute at UCLSarfond 31 Forskning Senil demensRegion Auvergne-Rhone-AlpesRegion Bourgogne-Franche-ComteRegion Hauts-de-FranceRegion Nouvelle-Aquitaine
  • BACKGROUND: Studies have suggested a connection between a decrease in the levels of polyunsaturated fatty acids (PUFAs) and Alzheimer's disease (AD). We aimed to assess the effect of supplementation with omega-3 fatty acids (n-3 FAs) on biomarkers analyzed in the cerebrospinal fluid (CSF) of patients diagnosed with AD.OBJECTIVE: To investigate the effects of daily supplementation with 2.3 g of PUFAs in AD patients on the biomarkers in CSF described below. We also explored the possible correlation between these biomarkers and the performance in the cognitive test Mini-Mental State Examination (MMSE).METHODS: Thirty-three patients diagnosed with AD were randomized to either treatment with a daily intake of 2.3 g of n-3 FAs (n  =  18) or placebo (n  =  15). CSF samples were collected at baseline and after six months of treatment, and the following biomarkers were analyzed: Aβ 38, Aβ 40, Aβ 42, t-tau, p-tau, neurofilament light (NfL), chitinase-3-like protein 1 (YKL-40), acetylcholinesterase (AChE), butyrylcholinesterase (BuChE), soluble IL-1 receptor type II (sIL-1RII), and IL-6.RESULTS: There were no significant differences between the groups concerning the level of the different biomarkers in the CSF at baseline. Within the treatment group, there was a small but significant increase in both YKL-40 (p = 0.04) and NfL (p = 0.03), while the other CSF biomarkers remained stable.CONCLUSION: Supplementation with n-3 FAs had a statistically significant effect on NfL and YKL-40, resulting in an increase of both biomarkers, indicating a possible increase of inflammatory response and axonal damage. This increase in biomarkers did not correlate with MMSE score.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Zetterberg, HenrikDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden; UK Dementia Research Institute at UCL, London, United Kingdom; Department of Neurodegenerative Disease, UCL Institute of Neurology, London, United Kingdom,Univ Gothenburg, Inst Neurosci & Physiol, Dept Psychiat & Neurochem, Sahlgrenska Acad, Mölndal, Sweden.;Sahlgrens Univ Hosp, Clin Neurochem Lab, Mölndal, Sweden.;UCL, UK Dementia Res Inst, London, England.;UCL Inst Neurol, Dept Neurodegenerat Dis, London, England. (författare)
  • Blennow, KajDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden,Univ Gothenburg, Inst Neurosci & Physiol, Dept Psychiat & Neurochem, Sahlgrenska Acad, Mölndal, Sweden.;Sahlgrens Univ Hosp, Clin Neurochem Lab, Mölndal, Sweden. (författare)
  • Basun, HansBioArctic AB, Stockholm, Sweden; Spinemedical AB, Stockholm, Sweden; Uppsala University Hospital, Uppsala, Sweden,BioArctic AB, Stockholm, Sweden.;Spinemed AB, Stockholm, Sweden.;Uppsala Univ Hosp, Uppsala, Sweden. (författare)
  • Cederholm, TommyUppsala universitet,Klinisk nutrition och metabolism,Karolinska Univ Hosp, Theme Ageing, Stockholm, Sweden.(Swepub:uu)tomce419 (författare)
  • Eriksdotter, MariaKarolinska Institutet,Karolinska Univ Hosp, Theme Ageing, Stockholm, Sweden.;Karolinska Inst, Ctr Alzheimer Res, Dept Neurobiol Care Sci & Soc, Div Clin Geriatr, Stockholm, Sweden. (författare)
  • Faxén-Irving, GerdKarolinska Institutet,Karolinska Inst, Ctr Alzheimer Res, Dept Neurobiol Care Sci & Soc, Div Clin Geriatr, Stockholm, Sweden. (författare)
  • Hjorth, ErikKarolinska Institutet,Karolinska Inst, Ctr Alzheimer Res, Dept Neurobiol Care Sci & Soc, Div Neurogeriatr, Stockholm, Sweden. (författare)
  • Jernerén, FredrikUppsala universitet,Institutionen för farmaceutisk biovetenskap(Swepub:uu)frjer991 (författare)
  • Schultzberg, MarianneKarolinska Institutet,Karolinska Inst, Ctr Alzheimer Res, Dept Neurobiol Care Sci & Soc, Div Neurogeriatr, Stockholm, Sweden. (författare)
  • Wahlund, Lars-OlofKarolinska Institutet,Karolinska Univ Hosp, Theme Ageing, Stockholm, Sweden.;Karolinska Inst, Ctr Alzheimer Res, Dept Neurobiol Care Sci & Soc, Div Clin Geriatr, Stockholm, Sweden. (författare)
  • Palmblad, JanKarolinska Institutet,Karolinska Inst, Karolinska Univ Hosp Huddinge, Dept Med, Stockholm, Sweden. (författare)
  • Freund-Levi, Yvonne,1956-Örebro universitet,Institutionen för medicinska vetenskaper,Department of Neurobiology, Care Sciences and Society, Division of Clinical Geriatrics, Center for Alzheimer Research, Karolinska Institutet, Stockholm, Sweden; Center for Alzheimer Research, Division of Clinical Geriatrics, Karolinska Institutet, Stockholm, Sweden; Department of Psychiatry, University Hospital Örebro, Örebro, Sweden; Department of Old Age Psychiatry, Psychology & Neuroscience, King's College London, London, United Kingdom,Örebro Univ, Sch Med, Örebro, Sweden.;Karolinska Inst, Ctr Alzheimer Res, Dept Neurobiol Care Sci & Soc, Div Clin Geriatr, Stockholm, Sweden.;Karolinska Inst, Ctr Alzheimer Res, Div Clin Geriatr, Stockholm, Sweden.;Univ Hosp Örebro, Dept Psychiat, Örebro, Sweden.;Kings Coll London, Dept Old Age Psychiat Psychol & Neurosci, London, England.(Swepub:oru)yfi (författare)
  • School of Medicine, Örebro University, Örebro, SwedenÖrebro Univ, Sch Med, Örebro, Sweden. (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:Journal of Alzheimer's Disease: IOS Press83:3, s. 1291-13011387-28771875-8908

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy